POINT Biopharma is a clinical-stage global pharmaceutical company focused on the development and commercialization of radioligand therapies for the treatment of cancer. In addition to our exciting pipeline of radioligand molecules for a variety of cancers, we also operate our own radiopharmaceutical production facility in Indianapolis, Indiana that is dedicated to produce our products.
Accelerating the discovery, development and global access to
“It is an incredibly exciting time for radiopharmaceuticals. Innovations in isotope production, combined with advancements in tumor targeting is enabling the creation of next-generation precision oncology medicines, some of which have already demonstrated promising efficacy with potentially fewer side effects than current treatment options. With two Phase 3 trials for radioligands to treat prostate and neuroendocrine cancers, an exciting early-stage pipeline, and a manufacturing facility in Indianapolis, I am excited by how strongly POINT is positioned to deliver on our mission, and look forward with great excitement to the future of our company.”
Dr. Joe McCann
Founder, CEO of POINT Biopharma
Stay up to date
Receive company announcements and news releases directly in your inbox by subscribing to POINT’s newsletter.